The Promise of Interferon-Free Treatment Regimens for Hepatitis C

Published Online: Friday, February 24, 2012
In a podcast from the American Gastroenterological Association, Anna S. Lok, MD, a professor in the department of internal medicine at the University of Michigan Health System, discussed an editorial titled “Interferon-Free Treatment Regimens for Hepatitis C: Are We There Yet?” that she coauthored in the December 2011 issue of Gastroenterology.
 
For approximately a decade up until 2011, the standard treatment for hepatitis C was a combination of interferon and ribavirin. The direct-acting antiviral agents telaprevir and boceprevir were approved last year as part of a triple-therapy regimen including interferon and ribavirin. In the interview, however, Dr. Lok explained that progress toward treating hepatitis C without interferon is proceeding very quickly.
 
Many hepatitis C patients are unable to tolerate interferon due to side effects, Dr. Lok explained, although clinicians also hope that an interferon-free treatment regimen could allow for a shorter duration of treatment and produce a higher response rate. She said that there are numerous trials underway to test interferon-free regimens and that some have already shown promising results. Pending the results of Phase 3 trials that should begin soon, Dr. Lok estimated that interferon-free regimens could be available within 3 to 5 years.
 
To listen to the interview, click here.
Latest Articles
This weekly video program highlights the latest in pharmacy news, product news, and more.
Propranolol is red, digoxin is blue. Your pharmacist’s heart may skip a beat if they get a valentine from you.
Health-system pharmacists can play a critical role in managing drug shortages to prevent medical errors and adverse events.
The White House is asking Congress for more than $1.8 billion in emergency funding to combat the Zika virus, which is creeping into the United States and ravaging some foreign countries.
Latest Issues
$auto_registration$